NEWS RELEASE

Teijin Starts Exclusive Sales of Merz’s Xeomin®
Botulinum Toxin Type A in JapanTokyo, Japan, December 4, 2020 --- Teijin Pharma Limited, the core company of theTeijin Group’s healthcare business, announced today that it starts exclusive sales ofXeomin® (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units on
December 4 for the treatment of upper limb spasticity. The drugs have been listed in theNational Health Insurance (NHI) drug price list on November 18.
Xeomin® is effective in treating peripheral cholinergic nerve endings by weakening thecontraction of voluntary muscles, and it relieves muscle tone by inhibiting the release of
a neurotransmitter called acetylcholine. The highly purified neurotoxin, the only active
ingredient in Xeomin®, is made by removing complexing proteins from botulinum toxin
type A, which is produced by Clostridium botulinum, using purification technology
developed by Merz Pharma GmbH & Co. KGaA. The lack of complexing proteins enables
Xeomin® to reduce the production of neutralizing antibodies capable of lowering efficacy.
A significant improvement in the modified ashworth scale (MAS) score of wrist flexion
was observed in the phase-III clinical trials in Japan.
Teijin Pharma signed an exclusive license and co-development agreement for Xeomin®
in Japan with Merz Pharma GmbH & Co. KGaA in 2017 and was granted approval by
Japan’s Ministry of Health, Labor and Welfare (MHLW) to market it for the treatment ofupper limb spasticity.
Upper limb spasticity is a symptom of upper motor neuron syndrome, which is expressed
mainly by increased muscle tone of upper limbs and the hyperexcitability of the stretch
reflex as a sequela of stroke. The main symptoms are motor paralysis, hyperflexion,
appearance of pathological reflexes, and sensory disturbances that complicate orimpede activities in daily living.
Conventional treatment of upper limb spasticity includes physical rehabilitation and theuse of oral muscle relaxants or neuromuscular blockers such as botulinum toxin type A.
Teijin Pharma already provides various pharmaceuticals including osteoporosis
treatment and medical devices such as sonic accelerated fracture healing system that
supports patients suffering from musculoskeletal diseases. The company has also
developed motor functions rehabilitation products such as electric stimulation device andportable robotic arm that supports the rehabilitation of paralyzed upper limbs. Teijin
Pharma continues to contribute to enhancing the quality of life (QOL) of patients byproviding new treatment options for diseases with high unmet needs.”About Xeomin®
Brand nameNonproprietaryname
Dosage form
Indication

Dosage andadministration

Xeomin® 50 units for intramuscular injection
Xeomin®100 units for intramuscular injection
Xeomin® 200 units for intramuscular injection

incobotulinumtoxinA
Injection (vial)
Upper limb spasticity
In general, for adults, Xeomin® should be injected into multiple tonic
muscles.* The maximum dose per administration is 400 units,
however, the dose should be appropriately reduced to the minimum
depending on the type and number of targeted tonic muscles.
Repeated doses are permissible if the effect of a previous dose
diminish. The dosing interval should be 12 weeks or longer, but
may be shortened to 10 weeks depending on the symptoms.
*Tonic muscles: flexor carpi radialis, flexor carpi ulnaris, flexor
digitorum dorsi, flexor digitorum brevis, radial biceps, biceps brachii,brachial musculature, pronation of the pronator, flexor progenitor,
flexor pollicis longus, adductor pollicis longus, flexor pollicis
brevis/opposite thumb muscle, etc.

Xeomin® is the registered trademark of Merz Pharma GmbH & Co. KGaA.

About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare
equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions,” Teijin aims to be a company thatsupports the society of the future. The group comprises more than 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 853.7 billion (USD 8.0 billion) and total assets of JPY 1,004.2 billion (USD9.4 billion) in the fiscal year that ended on March 31, 2020.
Please visit www.teijin.com